Leerink Swann Equities Analysts Boost Earnings Estimates for DOVA PHARMACUET (DOVA)

DOVA PHARMACUET (NASDAQ:DOVA) – Stock analysts at Leerink Swann increased their FY2021 earnings per share estimates for DOVA PHARMACUET in a research report issued to clients and investors on Friday. Leerink Swann analyst G. Porges now expects that the company will post earnings per share of $4.22 for the year, up from their prior forecast of $4.17. Leerink Swann has a “Market Perform” rating and a $24.00 price target on the stock.

Other analysts have also issued reports about the company. J P Morgan Chase & Co began coverage on DOVA PHARMACUET in a research note on Monday, July 24th. They set an “overweight” rating and a $35.00 price objective on the stock. Jefferies Group LLC began coverage on DOVA PHARMACUET in a research note on Monday, July 24th. They set a “buy” rating and a $30.00 price objective on the stock.

COPYRIGHT VIOLATION WARNING: This report was first reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this report on another domain, it was copied illegally and reposted in violation of United States & international trademark and copyright laws. The legal version of this report can be accessed at https://www.thecerbatgem.com/2017/08/15/leerink-swann-equities-analysts-boost-earnings-estimates-for-dova-pharmacuet-dova.html.

DOVA PHARMACUET (NASDAQ DOVA) traded up 1.05% during mid-day trading on Monday, hitting $22.04. The stock had a trading volume of 125,722 shares. The stock’s market capitalization is $550.78 million. The company’s 50 day moving average is $21.00 and its 200-day moving average is $21.00. DOVA PHARMACUET has a 52 week low of $16.98 and a 52 week high of $28.59.

DOVA PHARMACUET (NASDAQ:DOVA) last released its earnings results on Thursday, August 10th. The company reported ($0.32) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.24) by $0.08.

In other DOVA PHARMACUET news, Director Steven M. Goldman bought 72,000 shares of DOVA PHARMACUET stock in a transaction that occurred on Wednesday, July 5th. The stock was acquired at an average cost of $17.94 per share, for a total transaction of $1,291,680.00. Following the completion of the transaction, the director now directly owns 42,000 shares in the company, valued at $753,480. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Lee F. Md Phd Allen bought 3,500 shares of DOVA PHARMACUET stock in a transaction that occurred on Wednesday, July 5th. The shares were acquired at an average price of $17.00 per share, with a total value of $59,500.00. Following the completion of the transaction, the insider now owns 3,500 shares of the company’s stock, valued at $59,500. The disclosure for this purchase can be found here. Over the last quarter, insiders have purchased 101,800 shares of company stock worth $1,798,280.

A number of institutional investors have recently bought and sold shares of the company. Nexthera Capital LP acquired a new position in DOVA PHARMACUET during the second quarter valued at approximately $4,415,000. Goldman Sachs Group Inc. acquired a new position in DOVA PHARMACUET during the second quarter valued at approximately $493,000. Tudor Investment Corp ET AL acquired a new position in DOVA PHARMACUET during the second quarter valued at approximately $699,000. FMR LLC acquired a new position in DOVA PHARMACUET during the second quarter valued at approximately $43,969,000. Finally, Vanguard Group Inc. acquired a new position in DOVA PHARMACUET during the second quarter valued at approximately $390,000. Institutional investors and hedge funds own 0.20% of the company’s stock.

About DOVA PHARMACUET

Dova Pharmaceuticals, Inc is a clinical-stage pharmaceutical company. The Company is focused on acquiring, developing and commercializing drug candidates. The Company’s initial focus is on thrombocytopenia, a disorder characterized by a low blood platelet count. The Company is developing avatrombopag for treatment of thrombocytopenia in patients with chronic liver disease (CLD).

Receive News & Stock Ratings for DOVA PHARMACUET Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for DOVA PHARMACUET and related stocks with our FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *

*

4 − 2 =